JUN 05, 2019 10:25 AM PDT

Anti-Diabetic Drug Reduces Anxiety-Like Symptoms

WRITTEN BY: Nouran Amin

In a study published in the Journal of Neuroscience, an antidiabetic drug called metformin was found to alleviate anxiety-like behavioral symptoms in male mice.

The paper ‘Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids’ found that beyond its clinical relevance in diabetes—metformin increased serotonin availability in the brain. It’s important to note that metformin is a medication often prescribed to treat high blood sugar by reducing glucose production in the liver and increasing insulin sensitivity.

The present study demonstrated that the insulin-sensitizing drug metformin administered to mice on a high fat diet has reduced the levels of amino acids that impair tryptophan entry into the brain. Tryptophan is a precursor molecule that is converted to serotonin.

The antidepressant-like effects of the medication was accompanied by an improved neurotransmission in the hippocampus. Similar effects were achieved upon the reduction of the so-called branched chained amino acids in the diet.

Individuals with diabetes are often prone to mood disorders most commonly depression. Despite the mechanisms underlying the relationship remain unknown, some studies suggest that the precursor to diabetes –insulin resistance and its connection to depression may be pinpointed to a strong culprit, the neurotransmitter serotonin.

The increase of serotonin along with the reduction in anxiety-like behaviors are findings that can implicate treatments for patients with both metabolic and mental disorders.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 22, 2019
Drug Discovery
AUG 22, 2019
New Viable Drug Target for Prostate Cancer
In the research community, MYC is historically known to be a difficult oncogene to target in cancer therapy. However, a recent study in the Journal of Cell...
AUG 22, 2019
Drug Discovery
AUG 22, 2019
First Anticoagulant Approved for Pediatric Patients to Treat Potentially Life-Threatening Blood Clots
The approval of the drug Fragmin, an anti-coagulant subcutaneous use, will seek to reduce the recurrence of symptomatic venous thromboembolism (VTE) in ped...
AUG 22, 2019
Drug Discovery
AUG 22, 2019
New Drug Target for Chemically-Induced Parkinson Disease
Once upon a time, a compound found in synthetic opioid, MPTP induced the onset of Parkinson's disease. Early studies show that MPTP induces Parkinson d...
AUG 22, 2019
Microbiology
AUG 22, 2019
Cannabidiol has a Powerful Antimicrobial Effect
Cannabis plants produce at least sixty different cannabinoid compounds, which have different effects....
AUG 22, 2019
Drug Discovery
AUG 22, 2019
The Composition of Cerebrospinal Fluid in MS patients Could Be The Key To Treatments That Halt Progression
The range of disability for individuals living with multiple sclerosis (MS) varies significantly depending on the relapsing/remitting form of the disease....
AUG 22, 2019
Drug Discovery
AUG 22, 2019
Understanding The Anti-Malarial Drug Primaquine (PQ)
Scientists at the Liverpool School of Tropical Medicine (LSTM) have advanced their experiments to understand the mode of action for the anti-malarial drug ...
Loading Comments...